Last reviewed · How we verify
Bromocriptin
At a glance
| Generic name | Bromocriptin |
|---|---|
| Sponsor | University Hospital, Bonn |
| Target | 5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Acromegaly
- Hyperprolactinemia
- Parkinson's disease
- Postencephalitic parkinsonism
- Type 2 Diabetes Mellitus Treatment Adjunct
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Lightheadedness
- Vomiting
- Abdominal cramps
- Nasal congestion
- Constipation
- Diarrhea
- Drowsiness
- Postural/orthostatic hypotension
Serious adverse events
- Cerebrospinal fluid rhinorrhea
- Gastrointestinal bleeding
- Ventricular tachycardia
- Arrhythmia
- Syncope
- Delusional psychosis
- Paranoia
- Vasovagal attack
- Epileptiform seizure
- Ergotism
Key clinical trials
- Dopamine Action on Metabolism in Relation to Genotype (PHASE2)
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Bromocriptine for Patients With Schizophrenia and Prediabetes (PHASE4)
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (PHASE1, PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa (EARLY_PHASE1)
- Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |